CTOs on the Move

Highland Therapeutics

www.highlandtherapeutics.com

 
Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Highland Therapeutics raised $25M on 06/24/2015
Highland Therapeutics raised $200M on 01/24/2017

Similar Companies

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.

Detroit Wayne Mental Health Authority

DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.

BetaTec Hop Products

BetaTec Hop Products is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.

Nulixir

Nulixir is a B2B nanobiotechnology company that develops, manufactures, and licenses intellectual property for smart nanocarriers, called nanovesicles, which optimize the performance of functional ingredients in food & beverage products.